Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Tremendous growth opportunities |
| We're really well positioned |
| So, it's a really exciting opportunity |
| The profit margins, I'll tell you I'm being conservative when I say 20% to 25%, it's a very healthy profit margin for the business |
| The results are fantastic |
| So, it turns out our automation equipment works better than we expected when we include the lozenges line being installed in the coming months |
| Suffice it to say, we anticipate a significant improvement in the top-line and bottom-line sequentially each quarter moving forward, especially as we enter the second half of this year when Nebula B2B is anticipated to truly ramp up |
| They're creating some fantastic PR, which is going to bring great brand awareness, not only to ProPhase Labs, the public company, but also to Nebula Genomics |
| So, we have a much stronger finance team than we've ever had before |
| First of all, we have an incredible database, which has an amazing hidden asset value |
| And again, I'm really pleased now with how our management team has developed |
| Our results have been great |
| We have enough in our operating businesses between Pharmaloz and Nebula Genomics that if you're an investor, I think you're going to be incredibly pleased over the next one to two years with your investment especially at current stock prices |
| Obviously, it's an exciting opportunity for us |
| Suffice it to say we have a very strong management team |
| That'll bolster our claims, give us the best chance of success in rolling out the product |
| It turned out the automation equipment works better than we expected |
| We've had fantastic preclinical studies |
| All right, so in addition to that, so to be clear, what we did differently from what other microcap companies did, ThinkEquity, they did a fantastic job raising capital for us three-plus years ago |
| We have this fantastic proprietary reporting system |
| We could have been very successful in the clinical lab business, but maybe in a few years, it would be a $10 million or $20 million business and it could be worth $30 million or $40 million, whatever it is |
| I'm really excited about the future |
| And so that's why now I talk about it, I'm so excited about it |
| So with that, I'd also like to highlight just very quickly, we also have a fantastic relationship with ThinkEquity, our investment bankers, who we have had a three-and-a-half-year relationship with |
| It's really exciting what we're doing there |
| And so, I'm really excited for what's to come |
| And when all this comes together and because we have this new package designed for green, yellow, orange, red, it's a really exciting prospect for this test |
| So, we're in really good shape right now to build some very valuable businesses |
| All right? But we are very confident in what the product does |
| This all started because we've been in the business for six years and we have the best relationships |
| Statement |
|---|
| And so nobody even paid attention to us losing money for a quarter or two, and then it ramped up and exploded |
| And so, we have all these businesses that we're in late-stage negotiations with that could literally explode our business going forward |
| Just at the time, we were losing money |
| But in the short term, we're losing money at Nebula |
| And at the same time, the number of endoscopies goes down dramatically |
| But now pricing has come down |
| And the last thing I'll tell you is the few labs out there that could be considered competition to us, they're developing really bad reputations really quickly |
| Another possibility is that when we met with the large insurance companies, they told us there's a possibility that they will mandate this test |
| Not a bad track record |
| But what's interesting is the global demand for lozenges has gone through the roof and the capacity globally as well as in this country has actually shrunk, especially when we're talking about reliable capacity, it doesn't exist |
| I just don't know when but that's a surprise factor |
| The reason why whole genome sequencing has become so exciting now is because the prices dropped dramatically |
| Last year's financials, quite frankly, are irrelevant |
| Before we get into the Q&A, last year's first half had COVID testing, and the second half we had a significant transition and startup costs, especially in Q4 |
| If this takes hold, it's going to get scary |
| That's one possibility |
| And I couldn't be more excited about it |
| Obviously, as those profits grow, they can contribute to building out Nebula, but at some point Nebula is going to explode |
| It was so expensive historically, it wasn't a business for a big lab to do because it was too expensive |
| We have to see |
Please consider a small donation if you think this website provides you with relevant information